Opportunities for post-market surveillance of high cost medicines in Australia: Observing trastuzumab-treated women from early through late stage HER2-positive breast cancer (HER2BC)
ABSTRACT Objectives In 2001 the Australian government circumvented traditional drug subsidy listing processes to create the Herceptin Program (HP) for HER2 metastatic breast cancer (MBC) patients; in 2006 trastuzumab was subsidised for early breast cancer (EBC) on the Pharmaceutical Benefits Sche...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Swansea University
2017-04-01
|
| Series: | International Journal of Population Data Science |
| Online Access: | https://ijpds.org/article/view/142 |